Is it true that the risk of developing cancer increases with age?Bilikis (by SMS) Related Posts FG backs women in oncology leadership program to tackle cancer Climatic change: Community leader raises ...
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.